pentobarbital will decrease the level or result of midostaurin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Sturdy CYP3A4 inducers may well minimize midostaurin concentrations resulting in decreased efficacy.

pentobarbital will lower the extent or effect of dapsone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unidentified.

Steer clear of coadministration of ganaxolone with average or sturdy CYP3A4 inducers. If coadministration unavoidable, contemplate increasing ganaxolone dose; having said that, tend not to exceed utmost everyday dose for weight.

pentobarbital will minimize the extent or effect of finasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unfamiliar.

Consistently keep track of crucial symptoms throughout sedation and recovery time period if coadministered. Thoroughly titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.

pentobarbital will lessen the extent or impact of tipranavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will reduce the level or impact of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not advised; strong cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may reduce the therapeutic effectiveness

Observe Carefully (one)pentobarbital will lower the extent or result of cannabidiol by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

Stay clear of; coadministration with CYP3A inducers might cause diminished plasma concentrations of elvitegravir and/or read more simply a concomitantly administered protease inhibitor and lead to loss of therapeutic impact and also to achievable resistance

pentobarbital will lessen the extent or impact of doravirine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

fentanyl transmucosal and pentobarbital each improve sedation. Steer clear of or Use Alternate Drug. Limit use to patients for whom alternate procedure solutions are inadequate

pentobarbital will decrease the extent or outcome of osilodrostat by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.

pentobarbital will minimize the extent or influence of ramelteon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.